Fosun Pharma's US $18 million acquisition of the right to sell bial Parkinson's drugs in Portugal

Source: Sina pharmaceutical on January 8, 2018-1-11, Fosun Pharmaceutical acquired the exclusive sales right of new Parkinson's disease treatment drugs of bial pharmaceutical company of Portugal in mainland China for us $18 million The Parkinson's disease treatment drug ongentys ® (opicapone) developed by bial pharmaceutical company is a levodopa / dopa decarboxylase inhibitor Ongentys is a daily adjuvant therapy for adult patients with neurodegenerative movement disorder Parkinson's disease, as well as for those patients with Parkinson's disease who are unable to control the disease stably with the current therapy Ongentys is one of the catechol-O-methyltransferase (COMT) inhibitors COMT is one of the important metabolism enzymes of dopamine in vivo COMT inhibitors are the first-line drugs for Parkinson's disease patients, which are explicitly recommended by European, American and domestic treatment guidelines Ongentys was approved in the European Union in 2016 Wanbang pharmaceutical, a subsidiary of Fosun Pharmaceutical Holdings, will be responsible for the commercialization of the drug in China, with an upfront payment of $3 million and a milestone of up to $15 million.